Key result
KvLQT1 channel blockade reduces lung adenocarcinoma cell proliferation and migration.
Why the study?
Does KvLQT1 channel blockade reduce cell proliferation and migration in non-small cell lung cancer models?
Does KvLQT1 channel blockade reduce cell proliferation and migration in non-small cell lung cancer models?
Effect estimate: 1.5- to 7-fold increase
KvLQT1 channels are overexpressed in lung adenocarcinoma and their blockade reduces cancer cell proliferation and migration, highlighting a potential therapeutic target.
KvLQT1 blockade may merit preclinical testing in lung cancer; leaves open clinical translation pending prospective trials.
K+ channels, which are overexpressed in several cancers, have been identified as regulators of cell proliferation and migration, key processes in cancer development/propagation. Their role in lung cancer has not been studied extensively; but we showed previously that KvLQT1 channels are involved in cell migration, proliferation and repair of normal lung epithelial cells. We now investigated the role of these channels in lung cancer cell lines and their expression levels in human lung adenocarcinoma (AD) tissues. First, we observed that the wound-healing rates of A549 lung adenocarcinoma cell monolayers were reduced by clofilium and chromanol or after silencing with KvLQT1-specific siRNA. Dose-dependent decrease of A549 cell growth and cell accumulation in G0/G1 phase were seen after KvLQT1 inhibition. Clofilium also affected 2D and 3D migration of A549 cells. Similarly, H460 cell growth, migration and wound healing were diminished by this drug. Because K+ channel overexpression has been encountered in some cancers, we assessed KvLQT1 expression levels in tumor tissues from patients with lung AD. KvLQT1 protein expression in tumor samples was increased by 1.5- to 7-fold, compared to paired non-neoplastic tissues, in 17 of 26 patients. In summary, our data reveal that KvLQT1 channel blockade efficiently reduces A549 and H460 cell proliferation and migration. Moreover, KvLQT1 overexpression in AD samples suggests that it could be a potential therapeutic target in lung cancer.
No takes yet. Share an insight, caveat, or question.
Girault et al. (2013) studied Lung adenocarcinoma (n=26). KvLQT1 channel blockade (clofilium, chromanol, siRNA) vs. Untreated cells or negative control siRNA was evaluated on KvLQT1 protein expression in tumor vs non-neoplastic tissues (1.5- to 7-fold increase). KvLQT1 channel blockade reduced lung adenocarcinoma cell proliferation and migration, and KvLQT1 protein was overexpressed by 1.5- to 7-fold in tumor tissues from 17 of 26 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: